Startups
TargImmune Therapeutics AG is a private Swiss-based biotechnology company developing novel targeted immuno-oncology drugs that will improve the treatment for cancer patients. .
Overview
Location
Switzerland, Basel-City, Basel
Employees
11-50
Total raised
$19.22M
Founded date
2016
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 6
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 19, 2021 | TargImmune raises CHF17.7 million and appoints new CEO | |
| Sep 14, 2020 | Strong Swiss delegation at Bio Europe | Bio Europe, Europe’s largest platform designed for companies in the biotech and pharma sectors to meet and forge partnerships. Last year, the event hosted more than 4’400 visitors from 61 countries and 2300 companies. Over 27’300 one-to-one... |
| Sep 14, 2020 | Strong Swiss delegation at Bio Europe | |
| Apr 16, 2019 | €1.2 million to accelerate time to market | |
| Jul 11, 2017 | Race Oncology and Swiss-based start-up enter into a joint venture | The Race Immunotherapeutics joint venture will be a 50:50 partnership between Race and TargImmune, and all new intellectual property created by RITX will be equally co-owned by the parties through their ownership of the joint venture. RITX ... |
Reviews 0
FAQ about TargImmune Therapeutics AG
When was TargImmune Therapeutics AG founded?
TargImmune Therapeutics AG was founded in 2016.
How much funding has TargImmune Therapeutics AG raised?
TargImmune Therapeutics AG has raised $19.22M in total across 1 funding round.
What has the press written about TargImmune Therapeutics AG?
Parsers VC has collected 6 articles mentioning TargImmune Therapeutics AG, among them “TargImmune raises CHF17.7 million and appoints new CEO” (Jul 19, 2021) and “Strong Swiss delegation at Bio Europe” (Sep 14, 2020).
Is TargImmune Therapeutics AG still active?
Yes, TargImmune Therapeutics AG is active; its latest activity on Parsers VC dates from Mar 20, 2025.